Delisting Determination,The Nasdaq Stock Market, LLC,
July 5, 2016, Alexza Pharmaceuticals, Inc. The Nasdaq
Stock Market, Inc. (the Exchange) has determined to remove
from listing the common stock of Alexza Pharmaceuticals, Inc.
(the Company), effective at the opening of the trading
session on July 15, 2016. Based on review of information
provided by the Company, Nasdaq Staff determined that the
Company no longer qualified for listing on the Exchange
pursuant to Listing Rule 5550(b)(2). The Company was notified
of the Staffs determination on December 17, 2015.  The
Company appealed the determination to a Hearing Panel.
Upon review of the information provided by the Company,
the Panel issued a decision dated March 7, 2016, granting
the Company continued listing pursuant to an exception
that included several milestones that the Company was
required to meet, towards the goal of regaining compliance
with Listing Rule 5550(b)(2). However, the Company was
unable to meet the exception milestones as required on the
timeline set forth. Prior to the expiration of the exception
period the company signed an agreement to be acquired.
On June 15, 2016, the Panel issued a final delisting
determination and notified the Company that trading in the
Companys securities would be suspended on June 17, 2016.
Shortly thereafter, the company closed a going private
transaction, pursuant to which its equity securities
deregistered from the SEC and, thereby, all rights pertaining
to its class of securities listed on Nasdaq were extinguished.
The Company did not request a review of the Panels decision
by the Nasdaq Listing and Hearing Review Council.